deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT03016338

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib in Monotherapy or in Combination With Anti-PD1 Inhibitor TSR-042 in Recurrent Endometrial Cancer

Sponsor: Tesaro, Inc.

Conditions Endometrial Cancer
Interventions Niraparib TSR-042
Updated 14 times since 2017 Last updated: Jan 29, 2024 Started: Nov 6, 2017 Primary completion: Jan 5, 2021 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Endometrial Cancer and is currently ongoing. Tesaro, Inc. leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jan 2020 · 17 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jan 2022 · 8 months · monthly snapshot~Jan 2022 – ~Aug 2023 · 19 months · monthly snapshot~Aug 2023 – ~Feb 2024 · 6 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

14 versions recorded

  1. Feb 2026 — Present [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Aug 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  3. May 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Aug 2018 — Jan 2020 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  8. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Feb 2017 — Apr 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tesaro, Inc.
  • University Health Network, Toronto
Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations